Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline MelanomaSAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherape
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Institutional Investors Lost 5.0% Last Week but Have Benefitted From Longer-term Gains
Key Insights Significantly high institutional ownership implies Iovance Biotherapeutics' stock price is sensitive to their trading actions The top 9 shareholders own 51% of the company Insiders h
AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors
Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a first-of-its-kind cellular therapy recently approved by the U.S. Food and Drug Administration to treat metastatic melanoma.
Exelixis Slips as Barclays Downgrades on Lack of Catalysts
Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Better Growth Biotech Buy: Iovance Biotherapeutics Vs CRISPR Therapeutics
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (NASDAQ:IOVA) Pulls Back 5.6% This Week, but Still Delivers Shareholders Impressive 113% Return Over 1 Year
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shareholders might be concerned after seeing the share price drop 15% in the last month. But that doesn't change the fact that the returns over the last
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and deliv
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)
10 Health Care Stocks With Whale Alerts In Today's Session
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
Piper Sandler Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
Piper Sandler analyst Joseph Catanzaro maintains Iovance Biotherapeutics with a Overweight and raises the price target from $18 to $19.
Iovance Biotherapeutics (IOVA) Gets a Buy From Piper Sandler
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
Investors with a lot of money to spend have taken a bearish stance on Iovance Biotherapeutics (NASDAQ:IOVA).And retail traders should know.We noticed this today when the trades showed up on publicly a
Iovance Biotherapeutics Is Maintained at Buy by Truist Securities
Iovance Biotherapeutics Is Maintained at Buy by Truist Securities
Truist Securities Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $26
Truist Securities analyst Asthika Goonewardene maintains Iovance Biotherapeutics with a Buy and raises the price target from $17 to $26.
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
No Data